Amyloid imaging: Past, present and future perspectives

Ageing Research Reviews

Volumn 30, Issue , 2016, Pages 95-106

  Villemagne, Victor L ^a,b,c  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; A ; Brain imaging; Neurodegenerative disorders; Positron emission tomography

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CEREBROSPINAL FLUID; CLINICAL EFFECTIVENESS; DEMENTIA; DENDRITIC CELL; DIFFERENTIAL DIAGNOSIS; GLIOSIS; HUMAN; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SYNAPTIC POTENTIAL; AMYLOIDOSIS; ANIMAL; DIAGNOSTIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANIMALS; BIOMARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS;

EID: 84991752336     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2016.01.005     Document Type: Review

References (243)

1. Agdeppa, E.D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cloe, G.M., Small, G.W., Huang, S.C., Barrio, J.R., Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for ß-amyloid plaques in Alzheimer's disease. J. Neurosci., 21, 2001, RC189.
2. Agdeppa, E.D., Kepe, V., Shoghi-Jadid, K., et al. In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study. J. Nucl. Med., 2001.
3. Agdeppa, E.D., Kepe, V., Petri, A., Satyamurthy, N., Liu, J., Huang, S.C., Small, G.W., Cole, G.M., Barrio, J.R., In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile. Neuroscience 117 (2003), 723–730.
4. Aizenstein, H.J., Nebes, R.D., Saxton, J.A., Price, J.C., Mathis, C.A., Tsopelas, N.D., Ziolko, S.K., James, J.A., Snitz, B.E., Houck, P.R., Bi, W., Cohen, A.D., Lopresti, B.J., Dekosky, S.T., Halligan, E.M., Klunk, W.E., Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65 (2008), 1509–1517.
5. Albert, M.S., Dekosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., Holtzman, D.M., Jagust, W.J., Petersen, R.C., Snyder, P.J., Carrillo, M.C., Thies, B., Phelps, C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Demen. 7 (2011), 270–279.
6. Bacskai, B.J., Hickey, G.A., Skoch, J., Kajdasz, S.T., Wang, Y., Huang, G.F., Mathis, C.A., Klunk, W.E., Hyman, B.T., Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 12462–12467.
7. Barrio, J.R., Huang, S.C., Cole, G., Satyamurthy, N., Petric, A., Phelps, M.E., Small, G., PET imaging of tangles and plaques in Alzheimer disease with a highly lipophilic probe. J. Labelled Compd. Radiopharm. 42 (1999), S194–S195.
8. Barthel, H., Gertz, H.J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Hiemeyer, F., Wittemer-Rump, S.M., Seibyl, J., Reininger, C., Sabri, O., Cerebral amyloid-beta PET with florbetaben ((18)F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 10 (2011), 424–435.
9. Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., Cairns, N.J., Xie, X., Blazey, T.M., Holtzman, D.M., Santacruz, A., Buckles, V., Oliver, A., Moulder, K., Aisen, P.S., Ghetti, B., Klunk, W.E., McDade, E., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Schofield, P.R., Sperling, R.A., Salloway, S., Morris, J.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367 (2012), 795–804.
10. Bauer, M., Langer, O., Dal-Bianco, P., Karch, R., Brunner, M., Abrahim, A., Lanzenberger, R., Hofmann, A., Joukhadar, C., Carminati, P., Ghirardi, O., Piovesan, P., Forloni, G., Corrado, M.E., Lods, N., Dudczak, R., Auff, E., Kletter, K., Muller, M., A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin. Pharmacol. Ther. 80 (2006), 216–227.
11. Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C., Wilson, R.S., Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66 (2006), 1837–1844.
12. Benveniste, H., Einstein, G., Kim, K.R., Hulette, C., Johnson, G.A., Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 14079–14084.
13. Benzinger, T.L., Blazey, T., Jack, C.R. Jr., Koeppe, R.A., Su, Y., Xiong, C., Raichle, M.E., Snyder, A.Z., Ances, B.M., Bateman, R.J., Cairns, N.J., Fagan, A.M., Goate, A., Marcus, D.S., Aisen, P.S., Christensen, J.J., Ercole, L., Hornbeck, R.C., Farrar, A.M., Aldea, P., Jasielec, M.S., Owen, C.J., Xie, X., Mayeux, R., Brickman, A., McDade, E., Klunk, W., Mathis, C.A., Ringman, J., Thompson, P.M., Ghetti, B., Saykin, A.J., Sperling, R.A., Johnson, K.A., Salloway, S., Correia, S., Schofield, P.R., Masters, C.L., Rowe, C., Villemagne, V.L., Martins, R., Ourselin, S., Rossor, M.N., Fox, N.C., Cash, D.M., Weiner, M.W., Holtzman, D.M., Buckles, V.D., Moulder, K., Morris, J.C., Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E4502–4509.
14. Bobinski, M., de Leon, M.J., Convit, A., De Santi, S., Wegiel, J., Tarshish, C.Y., Saint Louis, L.A., Wisniewski, H.M., MRI of entorhinal cortex in mild Alzheimer's disease. Lancet 353 (1999), 38–40.
15. Braak, H., Braak, E., Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18 (1997), 351–357.
16. Bresjanac, M., Smid, L.M., Vovko, T.D., Petric, A., Barrio, J.R., Popovic, M., Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. J. Neurosci. 23 (2003), 8029–8033.
17. Camargo, E.E., Brain SPECT in neurology and psychiatry. J. Nucl. Med. 42 (2001), 611–623.
18. Camus, V., Payoux, P., Barre, L., Desgranges, B., Voisin, T., Tauber, C., La Joie, R., Tafani, M., Hommet, C., Chetelat, G., Mondon, K., de La Sayette, V., Cottier, J.P., Beaufils, E., Ribeiro, M.J., Gissot, V., Vierron, E., Vercouillie, J., Vellas, B., Eustache, F., Guilloteau, D., Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur. J. Nucl. Med. Mol. Imaging, 2012.
19. Cappai, R., White, A.R., Amyloid beta. Int. J. Biochem. Cell Biol. 31 (1999), 885–889.
20. Chang, C.Y., Silverman, D.H., Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Rev. Mol. Diagn. 4 (2004), 63–69.
21. Chetelat, G., Desgranges, B., de la Sayette, V., Viader, F., Berkouk, K., Landeau, B., Lalevee, C., Le Doze, F., Dupuy, B., Hannequin, D., Baron, J.C., Eustache, F., Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 126 (2003), 1955–1967.
22. Chetelat, G., Eustache, F., Viader, F., De La Sayette, V., Pelerin, A., Mezenge, F., Hannequin, D., Dupuy, B., Baron, J.C., Desgranges, B., FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11 (2005), 14–25.
23. Chetelat, G., Villemagne, V.L., Pike, K.E., Baron, J.C., Bourgeat, P., Jones, G., Faux, N.G., Ellis, K.A., Salvado, O., Szoeke, C., Martins, R.N., Ames, D., Masters, C.L., Rowe, C.C., Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133 (2010), 3349–3358.
24. Choi, S.R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T.E., Kilbourn, M.R., Skovronsky, D., Kung, H.F., Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 50 (2009), 1887–1894.
25. Clark, C.M., Davatzikos, C., Borthakur, A., Newberg, A., Leight, S., Lee, V.M., Trojanowski, J.Q., Biomarkers for early detection of Alzheimer pathology. Neurosignals 16 (2008), 11–18.
26. Clark, C.M., Schneider, J.A., Bedell, B.J., Beach, T.G., Bilker, W.B., Mintun, M.A., Pontecorvo, M.J., Hefti, F., Carpenter, A.P., Flitter, M.L., Krautkramer, M.J., Kung, H.F., Coleman, R.E., Doraiswamy, P.M., Fleisher, A.S., Sabbagh, M.N., Sadowsky, C.H., Reiman, E.P., Zehntner, S.P., Skovronsky, D.M., Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305 (2011), 275–283.
27. Clark, C.M., Pontecorvo, M.J., Beach, T.G., Bedell, B.J., Coleman, R.E., Doraiswamy, P.M., Fleisher, A.S., Reiman, E.M., Sabbagh, M.N., Sadowsky, C.H., Schneider, J.A., Arora, A., Carpenter, A.P., Flitter, M.L., Joshi, A.D., Krautkramer, M.J., Lu, M., Mintun, M.A., Skovronsky, D.M., Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 11 (2012), 669–678.
28. Cohen, R.M., Andreason, P.J., Doudet, D.J., Carson, R.E., Sunderland, T., Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. J. Neurol. Sci. 148 (1997), 171–180.
29. Cohen, A.D., Rabinovici, G.D., Mathis, C.A., Jagust, W.J., Klunk, W.E., Ikonomovic, M.D., Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv. Pharmacol. 64 (2012), 27–81.
30. Coleman, R.E., Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin. N. Am., 15, 2005 837-846, x.
31. Cselenyi, Z., Jonhagen, M.E., Forsberg, A., Halldin, C., Julin, P., Schou, M., Johnstrom, P., Varnas, K., Svensson, S., Farde, L., Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J. Nucl. Med. 53 (2012), 415–424.
32. Cummings, J.L., Vinters, H.V., Cole, G.M., Khachaturian, Z.S., Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51 (1998), S2–S17 discussion S65–S17.
33. Curtis, C., Gamez, J.E., Singh, U., Sadowsky, C.H., Villena, T., Sabbagh, M.N., Beach, T.G., Duara, R., Fleisher, A.S., Frey, K.A., Walker, Z., Hunjan, A., Holmes, C., Escovar, Y.M., Vera, C.X., Agronin, M.E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R., Ikonomovic, M.D., Sherwin, P.F., Grachev, I.D., Farrar, G., Smith, A.P., Buckley, C.J., McLain, R., Salloway, S., Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 72 (2015), 287–294.
34. Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R., Simms, G., Beyreuther, K., Masters, C.L., A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38 (1988), 1688–1693.
35. De Toledo-Morrell, L., Goncharova, I., Dickerson, B., Wilson, R.S., Bennett, D.A., From healthy aging to early Alzheimer's disease: in vivo detection of entorhinal cortex atrophy. Ann. N. Y. Acad. Sci. 911 (2000), 240–253.
36. Devanand, D.P., Jacobs, D.M., Tang, M.X., Del Castillo-Castaneda, C., Sano, M., Marder, K., Bell, K., Bylsma, F.W., Brandt, J., Albert, M., Stern, Y., The course of psychopathologic features in mild to moderate Alzheimer disease. Arch. Gen. Psychiatry 54 (1997), 257–263.
37. Dickerson, B.C., Goncharova, I., Sullivan, M.P., Forchetti, C., Wilson, R.S., Bennett, D.A., Beckett, L.A., deToledo-Morrell, L., MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol. Aging 22 (2001), 747–754.
38. Dierksen, G.A., Skehan, M.E., Khan, M.A., Jeng, J., Nandigam, R.N., Becker, J.A., Kumar, A., Neal, K.L., Betensky, R.A., Frosch, M.P., Rosand, J., Johnson, K.A., Viswanathan, A., Salat, D.H., Greenberg, S.M., Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Ann. Neurol. 68 (2010), 545–548.
39. Doraiswamy, P.M., Sperling, R.A., Coleman, R.E., Johnson, K.A., Reiman, E.M., Davis, M.D., Grundman, M., Sabbagh, M.N., Sadowsky, C.H., Fleisher, A.S., Carpenter, A., Clark, C.M., Joshi, A.D., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 79 (2012), 1636–1644.
40. Doraiswamy, P.M., Sperling, R.A., Johnson, K., Reiman, E.M., Wong, T.Z., Sabbagh, M.N., Sadowsky, C.H., Fleisher, A.S., Carpenter, A., Joshi, A.D., Lu, M., Grundman, M., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Group, A.A.S., Group, A.A.S., Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol. Psychiatry 19 (2014), 1044–1051.
41. Drzezga, A., Lautenschlager, N., Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., Schwaiger, M., Kurz, A., Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 30 (2003), 1104–1113.
42. Drzezga, A., Grimmer, T., Riemenschneider, M., Lautenschlager, N., Siebner, H., Alexopoulus, P., Minoshima, S., Schwaiger, M., Kurz, A., Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 46 (2005), 1625–1632.
43. Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J., Mathis, C.A., Klunk, W.E., Price, J., DeKosky, S., Wester, H.J., Schwaiger, M., Kurz, A., Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 39 (2008), 619–633.
44. Drzezga, A., Becker, J.A., Van Dijk, K.R., Sreenivasan, A., Talukdar, T., Sullivan, C., Schultz, A.P., Sepulcre, J., Putcha, D., Greve, D., Johnson, K.A., Sperling, R.A., Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134 (2011), 1635–1646.
45. Duara, R., Loewenstein, D.A., Shen, Q., Barker, W., Potter, E., Varon, D., Heurlin, K., Vandenberghe, R., Buckley, C., Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Demen., 2012.
46. Dubois, B., Feldman, H.H., Jacova, C., Dekosky, S.T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P.J., Scheltens, P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6 (2007), 734–746.
47. Dubois, B., Feldman, H.H., Jacova, C., Cummings, J.L., Dekosky, S.T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N.C., Galasko, D., Gauthier, S., Hampel, H., Jicha, G.A., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Sarazin, M., de Souza, L.C., Stern, Y., Visser, P.J., Scheltens, P., Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9 (2010), 1118–1127.
48. de Leon, M.J., Convit, A., DeSanti, S., Bobinski, M., George, A.E., Wisniewski, H.M., Rusinek, H., Carroll, R., Saint Louis, L.A., Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. Int. Psychogeriatr. 9 (1997), 183–190 discussion 247–152.
49. Fagan, A.M., Xiong, C., Jasielec, M.S., Bateman, R.J., Goate, A.M., Benzinger, T.L., Ghetti, B., Martins, R.N., Masters, C.L., Mayeux, R., Ringman, J.M., Rossor, M.N., Salloway, S., Schofield, P.R., Sperling, R.A., Marcus, D., Cairns, N.J., Buckles, V.D., Ladenson, J.H., Morris, J.C., Holtzman, D.M., Dominantly Inherited Alzheimer, N., Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci. Transl. Med., 6, 2014, 226ra230.
50. Falangola, M.F., Lee, S.P., Nixon, R.A., Duff, K., Helpern, J.A., Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem. Res. 30 (2005), 201–205.
51. Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., van Duijn, C.M., Effects of age sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997), 1349–1356.
52. Fleisher, A.S., Chen, K., Liu, X., Roontiva, A., Thiyyagura, P., Ayutyanont, N., Joshi, A.D., Clark, C.M., Mintun, M.A., Pontecorvo, M.J., Doraiswamy, P.M., Johnson, K.A., Skovronsky, D.M., Reiman, E.M., Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Neurol. 68 (2011), 1404–1411.
53. Fodero-Tavoletti, M.T., Smith, D.P., McLean, C.A., Adlard, P.A., Barnham, K.J., Foster, L.E., Leone, L., Perez, K., Cortes, M., Culvenor, J.G., Li, Q.X., Laughton, K.M., Rowe, C.C., Masters, C.L., Cappai, R., Villemagne, V.L., In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J. Neurosci. 27 (2007), 10365–10371.
54. Fodero-Tavoletti, M.T., Brockschnieder, D., Villemagne, V.L., Martin, L., Connor, A.R., Thiele, A., Berndt, M., McLean, C.A., Krause, S., Rowe, C.C., Masters, C.L., Dinkelborg, L., Dyrks, T., Cappai, R., In vitro characterization of [(18)F]-florbetaben, an Abeta imaging radiotracer. Nucl. Med. Biol. 39 (2012), 1042–1048.
55. Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Langstrom, B., Nordberg, A., PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29 (2008), 1456–1465.
56. Friedland, R.P., Shi, J., Lamanna, J.C., Smith, M.A., Perry, G., Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease. Ann. N. Y. Acad. Sci. 903 (2000), 123–128.
57. Furst, A.J., Rabinovici, G.D., Rostomian, A.H., Steed, T., Alkalay, A., Racine, C., Miller, B.L., Jagust, W.J., Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. Aging, 2010.
58. Ghilardi, J.R., Catton, M., Stimson, E.R., Rogers, S., Walker, L.C., Maggio, J.E., Mantyh, P.W., Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 7 (1996), 2607–2611.
59. Gomperts, S.N., Rentz, D.M., Moran, E., Becker, J.A., Locascio, J.J., Klunk, W.E., Mathis, C.A., Elmaleh, D.R., Shoup, T., Fischman, A.J., Hyman, B.T., Growdon, J.H., Johnson, K.A., Imaging amyloid deposition in Lewy body diseases. Neurology 71 (2008), 903–910.
60. Higuchi, M., Yanai, K., Okamura, N., Meguro, K., Arai, H., Itoh, M., Iwata, R., Ido, T., Watanabe, T., Sasaki, H., Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography. Neuroscience 99 (2000), 721–729.
61. Higuchi, M., Iwata, N., Matsuba, Y., Sato, K., Sasamoto, K., Saido, T.C., (19)F and (1)H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 8 (2005), 527–533.
62. Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., Mathis, C.A., Price, J.C., Tsopelas, N.D., Lopresti, B.J., Ziolko, S., Bi, W., Paljug, W.R., Debnath, M.L., Hope, C.E., Isanski, B.A., Hamilton, R.L., DeKosky, S.T., Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131 (2008), 1630–1645.
63. Ikonomovic, M.D., Abrahamson, E.E., Price, J.C., Hamilton, R.L., Mathis, C.A., Paljug, W.R., Debnath, M.L., Cohen, A.D., Mizukami, K., Dekosky, S.T., Lopez, O.L., Klunk, W.E., Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol. 123:3 (2012), 433–447.
64. Isacson, O., Seo, H., Lin, L., Albeck, D., Granholm, A.C., Alzheimers disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 25 (2002), 79–84.
65. Jack, C.R. Jr., Lowe, V.J., Senjem, M.L., Weigand, S.D., Kemp, B.J., Shiung, M.M., Knopman, D.S., Boeve, B.F., Klunk, W.E., Mathis, C.A., Petersen, R.C., 11C PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 131 (2008), 665–680.
66. Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., Pankratz, V.S., Senjem, M.L., Gunter, J.L., Mielke, M.M., Lowe, V.J., Boeve, B.F., Petersen, R.C., Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
67. Jagust, W., Reed, B., Mungas, D., Ellis, W., Decarli, C., What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 69 (2007), 871–877.
68. Jellinger, K.A., Bancher, C., Neuropathology of Alzheimer's disease: a critical update. J. Neural Transm. Suppl. 54 (1998), 77–95.
69. Jellinger, K., Morphology of Alzheimer disease and related disorders. Maurer, K., Riederer, P., Beckmann, H., (eds.) Alzheimer Disease: Epidemiology, Neuropathology, Neurochemistry, and Clinics, 1990, Springer-Verlag, Berlin, 61–77.
70. Johnson, K.A., Gregas, M., Becker, J.A., Kinnecom, C., Salat, D.H., Moran, E.K., Smith, E.E., Rosand, J., Rentz, D.M., Klunk, W.E., Mathis, C.A., Price, J.C., Dekosky, S.T., Fischman, A.J., Greenberg, S.M., Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol 62 (2007), 229–234.
71. Johnson, A.E., Jeppsson, F., Sandell, J., Wensbo, D., Neelissen, J.A., Jureus, A., Strom, P., Norman, H., Farde, L., Svensson, S.P., AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J. Neurochem. 108 (2009), 1177–1186.
72. Johnson, K.A., Minoshima, S., Bohnen, N.I., Donohoe, K.J., Foster, N.L., Herscovitch, P., Karlawish, J.H., Rowe, C.C., Carrillo, M.C., Hartley, D.M., Hedrick, S., Pappas, V., Thies, W.H., Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Demen., 2013 e-1-16.
73. Juottonen, K., Laakso, M.P., Insausti, R., Lehtovirta, M., Pitkanen, A., Patanen, K., Soininen, H., Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol. Aging 19 (1998), 15–22.
74. Jureus, A., Swahn, B.M., Sandell, J., Jeppsson, F., Johnson, A.E., Johnstrom, P., Neelissen, J.A., Sunnemark, D., Farde, L., Svensson, S.P., Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J. Neurochem. 114 (2010), 784–794.
75. Kemppainen, N., Ruottinen, H., Nagren, K., Rinne, J.O., PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 55 (2000), 205–209.
76. Kemppainen, N.M., Aalto, S., Wilson, I.A., Nagren, K., Helin, S., Bruck, A., Oikonen, V., Kailajarvi, M., Scheinin, M., Viitanen, M., Parkkola, R., Rinne, J.O., PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68 (2007), 1603–1606.
77. Kennedy, A.M., Frackowiak, R.S., Newman, S.K., Bloomfield, P.M., Seaward, J., Roques, P., Lewington, G., Cunningham, V.J., Rossor, M.N., Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186 (1995), 17–20.
78. Kepe, V., Barrio, J.R., Huang, S.C., Ercoli, L., Siddarth, P., Shoghi-Jadid, K., Cole, G.M., Satyamurthy, N., Cummings, J.L., Small, G.W., Phelps, M.E., Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 702–707.
79. Kepe, V., Ghetti, B., Farlow, M.R., Bresjanac, M., Miller, K., Huang, S.C., Wong, K.P., Murrell, J.R., Piccardo, P., Epperson, F., Repovs, G., Smid, L.M., Petric, A., Siddarth, P., Liu, J., Satyamurthy, N., Small, G.W., Barrio, J.R., PET of brain prion protein amyloid in Gerstmann-Straussler-Scheinker disease. Brain Pathol. 20 (2010), 419–430.
80. Kepe, V., Bordelon, Y., Boxer, A., Huang, S.C., Liu, J., Thiede, F.C., Mazziotta, J.C., Mendez, M.F., Donoghue, N., Small, G.W., Barrio, J.R., PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J. Alzheimers Dis. 36 (2013), 145–153.
81. Khachaturian, Z.S., Diagnosis of Alzheimer's disease. Arch. Neurol. 42 (1985), 1097–1105.
82. Kikuchi, T., Okamura, T., Zhang, M.R., Irie, T., PET probes for imaging brain acetylcholinesterase. J. Labelled Compd. Radiopharm. 56 (2013), 172–179.
83. Killiany, R.J., Gomez-Isla, T., Moss, M., Kikinis, R., Sandor, T., Jolesz, F., Tanzi, R., Jones, K., Hyman, B.T., Albert, M.S., Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol. 47 (2000), 430–439.
84. Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Mathis, C.A., Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69 (2001), 1471–1484.
85. Klunk, W.E., Bacskai, B.J., Mathis, C.A., Kajdasz, S.T., McLellan, M.E., Frosch, M.P., Debnath, M.L., Holt, D.P., Wang, Y., Hyman, B.T., Imaging Aß plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropath Exp. Neurol. 61 (2002), 797–805.
86. Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Shao, L., Hamilton, R.L., Ikonomovic, M.D., DeKosky, S.T., Mathis, C.A., The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 23 (2003), 2086–2092.
87. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergström, M., Savitcheva, I., Huang, G.F., Estrada, S., Ausén, B., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Långström, B., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004), 306–319.
88. Klunk, W.E., Price, J.C., Mathis, C.A., Tsopelas, N.D., Lopresti, B.J., Ziolko, S.K., Bi, W., Hoge, J.A., Cohen, A.D., Ikonomovic, M.D., Saxton, J.A., Snitz, B.E., Pollen, D.A., Moonis, M., Lippa, C.F., Swearer, J.M., Johnson, K.A., Rentz, D.M., Fischman, A.J., Aizenstein, H.J., DeKosky, S.T., Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27 (2007), 6174–6184.
89. Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., Itoh, M., Iwata, R., Yanai, K., Arai, H., 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy) benzoxazole: a novel pet agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J. Nucl. Med. 48 (2007), 553–561.
90. Kung, H.F., Lee, C.W., Zhuang, Z.P., Kung, M.P., Hou, C., Plossl, K., Novel stilbenes as probes for amyloid plaques. J. Am. Chem. Soc. 123 (2001), 12740–12741.
91. Kung, M.P., Hou, C., Zhuang, Z.P., Zhang, B., Skovronsky, D., Trojanowski, J.Q., Lee, V.M., Kung, H.F., IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res. Bull. 956 (2002), 202–210.
92. Kung, M.P., Skovronsky, D.M., Hou, C., Zhuang, Z.P., Gur, T.L., Zhang, B., Trojanowski, J.Q., Lee, V.M., Kung, H.F., Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. J. Mol. Neurosci. 20 (2003), 15–24.
93. Kung, M.P., Hou, C., Zhuang, Z.P., Skovronsky, D., Kung, H.F., Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res. 1025 (2004), 98–105.
94. Kurihara, A., Pardridge, W.M., Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)in chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjug. Chem. 11 (2000), 380–386.
95. Landau, S.M., Harvey, D., Madison, C.M., Koeppe, R.A., Reiman, E.M., Foster, N.L., Weiner, M.W., Jagust, W.J., Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging, 2009.
96. Landau, S.M., Thomas, B.A., Thurfjell, L., Schmidt, M., Margolin, R., Mintun, M., Pontecorvo, M., Baker, S.L., Jagust, W.J., the Alzheimer's Disease Neuroimaging, I, Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging, 2014.
97. Larson, E.B., Edwards, J.K., O'Meara, E., Nochlin, D., Sumi, S.M., Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J. Gerontol. A Biol. Sci. Med. Sci. 51:Suppl. 6 (1996), M313–M318.
98. LeVine, H. 3rd, Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309 (1999), 274–284.
99. Lee, C.W., Zhuang, Z.P., Kung, M.P., Plossl, K., Skovronsky, D., Gur, T., Hou, C., Trojanowski, J.Q., Lee, V.M., Kung, H.F., Isomerization of (Z,Z) to (E,E) 1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy) styrylbenzene in strong base: probes for amyloid plaques in the brain. J. Med. Chem. 44 (2001), 2270–2275.
100. Lee, V.M., Related Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol. Aging 23 (2002), 1039–1042.
101. Leyton, C.E., Villemagne, V.L., Savage, S., Pike, K.E., Ballard, K.J., Piguet, O., Burrell, J.R., Rowe, C.C., Hodges, J.R., Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using beta-amyloid imaging. Brain 134 (2011), 3030–3043.
102. Lin, K.S., Debnath, M.L., Mathis, C.A., Klunk, W.E., Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. Bioorg. Med. Chem. Lett 19 (2009), 2258–2262.
103. Link, C.D., Johnson, C.J., Fonte, V., Paupard, M., Hall, D.H., Styren, S., Mathis, C.A., Klunk, W.E., Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol. Aging 22 (2001), 217–226.
104. Lister-James, J., Pontecorvo, M.J., Clark, C., Joshi, A.D., Mintun, M.A., Zhang, W., Lim, N., Zhuang, Z., Golding, G., Choi, S.R., Benedum, T.E., Kennedy, P., Hefti, F., Carpenter, A.P., Kung, H.F., Skovronsky, D.M., Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. Semin. Nucl. Med. 41 (2011), 300–304.
105. Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., Joyce, J.N., Ye, L., Libri, V., Leppert, D., Beach, T.G., PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130 (2007), 2607–2615.
106. Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C., Leyhe, T., Keller, S., Melms, A., Gasser, T., Berg, D., Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis. 34 (2009), 107–112.
107. Maezawa, I., Hong, H.S., Liu, R., Wu, C.Y., Cheng, R.H., Kung, M.P., Kung, H.F., Lam, K.S., Oddo, S., Laferla, F.M., Jin, L.W., Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem. 104 (2008), 457–468.
108. Majocha, R.E., Reno, J.M., Friedland, R.P., Van Haight, C., Lyle, L.R., Marotta, C.A., Development of a monoclonal antibody specific for ß/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J. Nucl. Med. 33 (1992), 2184–2189.
109. Marshall, J.R., Stimson, E.R., Ghilardi, J.R., Vinters, H.V., Mantyh, P.W., Maggio, J.E., Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjug. Chem. 13 (2002), 276–284.
110. Masters, C.L., Beyreuther, K., The neuropathology of Alzheimer's disease in the year 2005. Beal, M.F., Lang, A.E., Ludolph, A.C., (eds.) Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics, 2005, Cambridge University Press, Cambridge, 433–440.
111. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 4245–4249.
112. Masters, C.L., Neuropathology of Alzheimer's disease. Burns, A., O'Brien, J., Ames, D., (eds.) Dementia, 3rd ed., 2005, Hodder Arnold, London, 393–407.
113. Mathis, C.A., Holt, D.P., Wang, Y., Huang, G.F., Debnath, M.L., Klunk, W.E., Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. J. Labelled Cpd. Radiopharm. 44 (2001), S26–S28.
114. Mathis, C.A., Bacskai, B.J., Kajdasz, S.T., McLellan, M.E., Frosch, M.P., Hyman, B.T., Holt, D.P., Wang, Y., Huang, G.F., Debnath, M.L., Klunk, W.E., A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12 (2002), 295–298.
115. Mathis, C.A., Wang, Y., Holt, D.P., Huang, G.F., Debnath, M.L., Klunk, W.E., Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46 (2003), 2740–2754.
116. Mathis, C.A., Klunk, W.E., Price, J.C., DeKosky, S.T., Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch. Neurol. 62 (2005), 196–200.
117. McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q., Yamada, M., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:12 (2005), 1863–1872.
118. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical Diagnosis of Alzheimers Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
119. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S., Phelps, C.H., The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Demen. 7 (2011), 263–269.
120. Michaelis, M.L., Dobrowsky, R.T., Li, G., Tau neurofibrillary pathology and microtubule stability. J. Mol. Neurosci. 19 (2002), 289–293.
121. Mills, S.M., Mallmann, J., Santacruz, A.M., Fuqua, A., Carril, M., Aisen, P.S., Althage, M.C., Belyew, S., Benzinger, T.L., Brooks, W.S., Buckles, V.D., Cairns, N.J., Clifford, D., Danek, A., Fagan, A.M., Farlow, M., Fox, N., Ghetti, B., Goate, A.M., Heinrichs, D., Hornbeck, R., Jack, C., Jucker, M., Klunk, W.E., Marcus, D.S., Martins, R.N., Masters, C.M., Mayeux, R., McDade, E., Morris, J.C., Oliver, A., Ringman, J.M., Rossor, M.N., Salloway, S., Schofield, P.R., Snider, J., Snyder, P., Sperling, R.A., Stewart, C., Thomas, R.G., Xiong, C., Bateman, R.J., Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev. Neurol. (Paris) 169 (2013), 737–743.
122. Mintun, M.A., Larossa, G.N., Sheline, Y.I., Dence, C.S., Lee, S.Y., Mach, R.H., Klunk, W.E., Mathis, C.A., DeKosky, S.T., Morris, J.C., [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67 (2006), 446–452.
123. Mormino, E.C., Kluth, J.T., Madison, C.M., Rabinovici, G.D., Baker, S.L., Miller, B.L., Koeppe, R.A., Mathis, C.A., Weiner, M.W., Jagust, W.J., Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132 (2009), 1310–1323.
124. Morris, J.C., Price, A.L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimers disease. J. Mol. Neurosci. 17 (2001), 101–118.
125. Morris, J.C., Kimberly, A., Quaid, K., Holtzman, D.M., Kantarci, K., Kaye, J., Reiman, E.M., Klunk, W.E., Siemers, E.R., Role of biomarkers in studies of presymptomatic Alzheimers disease. Alzheimers Demen. 1 (2005), 145–151.
126. Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Holtzman, D.M., Mintun, M.A., Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66 (2009), 1469–1475.
127. Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M., Mintun, M.A., APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 67 (2010), 122–131.
128. Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Baron, J.C., De Cristofaro, M.T., Padovani, A., Borroni, B., Franceschi, M., Bracco, L., Pupi, A., MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63 (2004), 2332–2340.
129. Mosconi, L., De Santi, S., Li, Y., Li, J., Zhan, J., Tsui, W.H., Boppana, M., Pupi, A., de Leon, M.J., Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimers disease using FDG-PET. Eur. J. Nucl. Med. Mol. Imaging 33 (2006), 210–221.
130. Mosconi, L., Sorbi, S., de Leon, M.J., Li, Y., Nacmias, B., Myoung, P.S., Tsui, W., Ginestroni, A., Bessi, V., Fayyazz, M., Caffarra, P., Pupi, A., Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimers disease. J. Nucl. Med. 47 (2006), 1778–1786.
131. Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P., Buxbaum, J.D., Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000), 1571–1577.
132. Nelissen, N., Van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D.J., Vandenberghe, R., Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 50 (2009), 1251–1259.
133. Nelson, L.D., Siddarth, P., Kepe, V., Scheibel, K.E., Huang, S.C., Barrio, J.R., Small, G.W., Positron emission tomography of brain beta-amyloid and tau levels in adults with Down syndrome. Arch. Neurol. 68 (2011), 768–774.
134. Ng, S.Y., Villemagne, V.L., Masters, C.L., Rowe, C.C., Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Arch. Neurol. 64 (2007), 1140–1144.
135. Noda, A., Murakami, Y., Nishiyama, S., Fukumoto, D., Miyoshi, S., Tsukada, H., Nishimura, S., Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. Synapse 62 (2008), 472–475.
136. Nordberg, A., Hartvig, P., Lilja, A., Viitanen, M., Amberla, K., Lundqvist, H., Andersson, J., Nyback, H., Ulin, J., Anderson, Y., et al. Nicotine receptors in the brain of patients with Alzheimers disease. Studies with 11C-nicotine and positron emission tomography. Acta Radiol. Suppl. 376 (1991), 165–166.
137. Nordberg, A., Clinical studies in Alzheimer patients with positron emission tomography. Behav. Brain Res. 57 (1993), 215–224.
138. Nordberg, A., In vivo detection of neurotransmitter changes in Alzheimers disease. Ann. N. Y. Acad. Sci. 695 (1993), 27–33.
139. Nyberg, S., Jonhagen, M.E., Cselenyi, Z., Halldin, C., Julin, P., Olsson, H., Freund-Levi, Y., Andersson, J., Varnas, K., Svensson, S., Farde, L., Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur. J. Nucl. Med. Mol. Imaging 36 (2009), 1859–1863.
140. Okamura, N., Funaki, Y., Tashiro, M., Kato, M., Ishikawa, Y., Maruyama, M., Ishikawa, H., Meguro, K., Iwata, R., Yanai, K., In vivo visualization of donepezil binding in the brain of patients with Alzheimers disease. Br. J. Clin. Pharmacol. 65 (2008), 472–479.
141. Ong, K., Villemagne, V.L., Bahar-Fuchs, A., Lamb, F., Chetelat, G., Raniga, P., Mulligan, R.S., Salvado, O., Putz, B., Roth, K., Masters, C.L., Reininger, C.B., Rowe, C.C., (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res. Ther., 5, 2013, 4.
142. Ong, K.T., Villemagne, V.L., Bahar-Fuchs, A., Lamb, F., Langdon, N., Catafau, A.M., Stephens, A.W., Seibyl, J., Dinkelborg, L.M., Reininger, C.B., Putz, B., Rohde, B., Masters, C.L., Rowe, C.C., Abeta imaging with 18F-florbetaben in prodromal Alzheimers disease: a prospective outcome study. J. Neurol. Neurosurg. Psychiatry, 2014.
143. Ono, M., Wilson, A., Nobrega, J., Westaway, D., Verhoeff, P., Zhuang, Z.P., Kung, M.P., Kung, H.F., 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimers disease. Nucl. Med. Biol. 30 (2003), 565–571.
144. Ossenkoppele, R., Tolboom, N., Foster-Dingley, J.C., Adriaanse, S.F., Boellaard, R., Yaqub, M., Windhorst, A.D., Barkhof, F., Lammertsma, A.A., Scheltens, P., van der Flier, W.M., van Berckel, B.N., Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur. J. Nucl. Med. Mol. Imaging 39 (2012), 990–1000.
145. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D.J., Klunk, W.E., Ashford, E., Yoo, K., Xu, Z.X., Loetscher, H., Santarelli, L., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol., 2011.
146. Petersen, R.C., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Schaid, D.J., Thibodeau, S.N., Kokmen, E., Waring, S.C., Kurland, L.T., Apolipoprotein E status as a predictor of the development of Alzheimers disease in memory-impaired individuals. JAMA 273 (1995), 1274–1278.
147. Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., Kokmen, E., Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56 (1999), 303–308.
148. Petersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L., DeKosky, S.T., Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review)-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001), 1133–1142.
149. Petersen, R.C., Mild cognitive impairment: transition between aging and Alzheimers disease. Neurologia 15 (2000), 93–101.
150. Phelps, M.E., PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41 (2000), 661–681.
151. Piggott, M.A., Owens, J., O'Brien, J., Colloby, S., Fenwick, J., Wyper, D., Jaros, E., Johnson, M., Perry, R.H., Perry, E.K., Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinsons disease and Alzheimers disease. J. Chem. Neuroanat. 25 (2003), 161–173.
152. Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., Mathis, C.A., Klunk, W.E., Masters, C.L., Rowe, C.C., Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimers disease. Brain 130 (2007), 2837–2844.
153. Price, J.L., Morris, J.C., Tangles and plaques in nondemented aging and preclinical Alzheimers disease. Ann. Neurol. 45 (1999), 358–368.
154. Price, J.C., Klunk, W.E., Lopresti, B.J., Lu, X., Hoge, J.A., Ziolko, S.K., Holt, D.P., Meltzer, C.C., DeKosky, S.T., Mathis, C.A., Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 25 (2005), 1528–1547.
155. Rabinovici, G.D., Furst, A.J., O'Neil, J.P., Racine, C.A., Mormino, E.C., Baker, S.L., Chetty, S., Patel, P., Pagliaro, T.A., Klunk, W.E., Mathis, C.A., Rosen, H.J., Miller, B.L., Jagust, W.J., 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68 (2007), 1205–1212.
156. Rabinovici, G.D., Jagust, W.J., Furst, A.J., Ogar, J.M., Racine, C.A., Mormino, E.C., O'Neil, J.P., Lal, R.A., Dronkers, N.F., Miller, B.L., Gorno-Tempini, M.L., Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann. Neurol. 64 (2008), 388–401.
157. Rasmusson, D.X., Brandt, J., Steele, C., Hedreen, J.C., Troncoso, J.C., Folstein, M.F., Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology. Alzheimer Dis. Assoc. Disord. 10 (1996), 180–188.
158. Reiman, E.M., Caselli, R.J., Yun, L.S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S.N., Osborne, D., Preclinical evidence of Alzheimers disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334 (1996), 752–758.
159. Reiman, E.M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S.A., Langbaum, J.B., Alexander, G.E., Klunk, W.E., Mathis, C.A., Price, J.C., Aizenstein, H.J., DeKosky, S.T., Caselli, R.J., Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimers disease. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 6820–6825.
160. Reiman, E.M., Langbaum, J.B., Fleisher, A.S., Caselli, R.J., Chen, K., Ayutyanont, N., Quiroz, Y.T., Kosik, K.S., Lopera, F., Tariot, P.N., Alzheimers Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26:Suppl. 3 (2011), 321–329.
161. Rentz, D.M., Locascio, J.J., Becker, J.A., Moran, E.K., Eng, E., Buckner, R.L., Sperling, R.A., Johnson, K.A., Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 67 (2010), 353–364.
162. Resnick, S.M., Sojkova, J., Zhou, Y., An, Y., Ye, W., Holt, D.P., Dannals, R.F., Mathis, C.A., Klunk, W.E., Ferrucci, L., Kraut, M.A., Wong, D.F., Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74 (2010), 807–815.
163. Rinne, J.O., Brooks, D.J., Rossor, M.N., Fox, N.C., Bullock, R., Klunk, W.E., Mathis, C.A., Blennow, K., Barakos, J., Okello, A.A., Rodriguez Martinez de Liano, S., Liu, E., Koller, M., Gregg, K.M., Schenk, D., Black, R., Grundman, M., 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9 (2010), 363–372.
164. Roe, C.M., Mintun, M.A., D'Angelo, G., Xiong, C., Grant, E.A., Morris, J.C., Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch. Neurol. 65 (2008), 1467–1471.
165. Rossor, M.N., Kennedy, A.M., Frackowiak, R.S., Clinical and neuroimaging features of familial Alzheimers disease. Ann. N. Y. Acad. Sci. 777 (1996), 49–56.
166. Rowe, C.C., Villemagne, V.L., Brain amyloid imaging. J. Nucl. Med. 52 (2011), 1733–1740.
167. Rowe, C.C., Ng, S., Ackermann, U., Gong, S.J., Pike, K., Savage, G., Cowie, T.F., Dickinson, K.L., Maruff, P., Darby, D., Smith, C., Woodward, M., Merory, J., Tochon-Danguy, H., O'Keefe, G., Klunk, W.E., Mathis, C.A., Price, J.C., Masters, C.L., Villemagne, V.L., Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
168. Rowe, C.C., Ackerman, U., Browne, W., Mulligan, R., Pike, K.L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S.U., Jones, G., Dickinson-Rowe, K.L., Kung, H.P., Zhang, W., Kung, M.P., Skovronsky, D., Dyrks, T., Holl, G., Krause, S., Friebe, M., Lehman, L., Lindemann, S., Dinkelborg, L.M., Masters, C.L., Villemagne, V.L., Imaging of amyloid beta in Alzheimers disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7 (2008), 129–135.
169. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., Price, R., Raniga, P., Robins, P., Acosta, O., Lenzo, N., Szoeke, C., Salvado, O., Head, R., Martins, R., Masters, C.L., Ames, D., Villemagne, V.L., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31 (2010), 1275–1283.
170. Rowe, C.C., Bourgeat, P., Ellis, K.A., Brown, B., Lim, Y.Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., Robins, P., Tochon-Danguy, H., O'Keefe, G., Pike, K.E., Yates, P., Szoeke, C., Salvado, O., Macaulay, S.L., O'Meara, T., Head, R., Cobiac, L., Savage, G., Martins, R., Masters, C.L., Ames, D., Villemagne, V.L., Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann. Neurol. 74 (2013), 905–913.
171. Rowe, C.C., Pejoska, S., Mulligan, R.S., Jones, G., Chan, J.G., Svensson, S., Cselenyi, Z., Masters, C.L., Villemagne, V.L., Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J. Nucl. Med. 54 (2013), 880–886.
172. Sabri, O., Sabbagh, M.N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., Beach, T.G., Rowe, C.C., Leverenz, J.B., Ghetti, B., Ironside, J.W., Catafau, A.M., Stephens, A.W., Mueller, A., Koglin, N., Hoffmann, A., Roth, K., Reininger, C., Schulz-Schaeffer, W.J., Florbetaben Phase 3 Study, G., 2015. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Demen. 11 (2015), 964–974.
173. Saito, Y., Buciak, J., Yang, J., Pardridge, W.M., Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1–40 through the blood–brain barrier and binding to Alzheimer disease amyloid of the A beta 1–0/vector complex. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 10227–10231.
174. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I.C., Liu, E.C., Grundman, M., Yuen, E., Black, R., Brashear, H.R., Clinical, B., Two Phase 3 Trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370 (2014), 322–333.
175. Salmon, E., Sadzot, B., Maquet, P., Degueldre, C., Lemaire, C., Rigo, P., Comar, D., Franck, G., Differential diagnosis of Alzheimer'’s disease with PET. J. Nucl.Med. 35 (1994), 391–398.
176. Sato, K., Higuchi, M., Iwata, N., Saido, T.C., Sasamoto, K., Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 39 (2004), 573–578.
177. Sedvall, G., Nyback, H., Farde, L., Persson, A., Neurotransmitter receptor imaging in Alzheimer's disease. J. Neural Transm. Suppl. 24 (1987), 43–48.
178. Selkoe, D.J., The early diagnosis of Alzheimer's disease. Scinto, L.F.M., Daffner, K.R., (eds.) The Pathophysiology of Alzheimer's Disease, 2000, Humana, Totowa, NJ, 83–104.
179. Serdons, K., Terwinghe, C., Vermaelen, P., Van Laere, K., Kung, H., Mortelmans, L., Bormans, G., Verbruggen, A., Synthesis and evaluation of (18)F-labeled 2-phenylbenzothiazoles as positron emission tomography imaging agents for amyloid plaques in Alzheimer's disease. J. Med. Chem., 2009.
180. Serdons, K., Verduyckt, T., Vanderghinste, D., Cleynhens, J., Borghgraef, P., Vermaelen, P., Terwinghe, C., Van Leuven, F., Van Laere, K., Kung, H., Bormans, G., Verbruggen, A., Synthesis of 18F-labelled 2-(4′-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB. Bioorg. Med. Chem. Let. 19 (2009), 602–605.
181. Shi, J., Perry, G., Berridge, M.S., Aliev, G., Siedlak, S.L., Smith, M.A., LaManna, J.C., Friedland, R.P., Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J. Nucl. Med. 43 (2002), 1044–1051.
182. Shimadzu, H., Suemoto, T., Suzuki, M., Shiomitsu, T., Okamura, N., Kudo, Y., Sawada, T., A novel probe for imaging amyloid-b: Synthesis of F-18 labelled BF-108, an Acridine Orange analog. J. Labelled Compd. Radiopharm. 46 (2003), 765–772.
183. Shin, J., Lee, S.Y., Kim, S.H., Kim, Y.B., Cho, S.J., Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 43 (2008), 236–244.
184. Shoghi-Jadid, K., Small, G.W., Agdeppa, E.D., Kepe, V., Ercoli, L.M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S.C., Barrio, J.R., Localisation of neurofibrillary tangles and ß-amyloid plaques in the brains of living patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry 10 (2002), 24–35.
185. Silverman, D.H., Phelps, M.E., Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke. Mol. Genet. Metab. 74 (2001), 128–138.
186. Silverman, D.H., Chang, C.Y., Cummings, J.L., Kowell, A.P., Czernin, J., Small, G.W., Gambhir, S.S., Hoh, C.K., Phelps, M.E., Prognostic value of regional brain metabolism in evaluation of dementia. J. Nucl. Med., 40, 1999, 71P.
187. Silverman, D.H., Small, G.W., Chang, C.Y., Lu, C.S., Kung De Aburto, M.A., Chen, W., Czernin, J., Rapoport, S.I., Pietrini, P., Alexander, G.E., Schapiro, M.B., Jagust, W.J., Hoffman, J.M., Welsh-Bohmer, K.A., Alavi, A., Clark, C.M., Salmon, E., de Leon, M.J., Mielke, R., Cummings, J.L., Kowell, A.P., Gambhir, S.S., Hoh, C.K., Phelps, M.E., Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286 (2001), 2120–2127.
188. Silverman, D.H., Cummings, J.L., Small, G.W., Gambhir, S.S., Chen, W., Czernin, J., Phelps, M.E., Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol. Imaging Biol. 4 (2002), 283–293.
189. Silverman, D.H., Gambhir, S.S., Huang, H.W., Schwimmer, J., Kim, S., Small, G.W., Chodosh, J., Czernin, J., Phelps, M.E., Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J. Nucl. Med. 43 (2002), 253–266.
190. Skovronsky, D.M., Zhang, B., Kung, M.P., Kung, H.F., Trojanowski, J.Q., Lee, V.M., In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 7609–7614.
191. Small G.W., Mazziotta J.C., Collins M.T., Baxter L.R., Phelps M.E., Mandelkern M.A., Kaplan A., La Rue A., Adamson C.F., Chang, L., al., e., 1995. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942–947.
192. Small, G.W., Agdeppa, E.D., Kepe, V., Satyamurthy, N., Huang, S.C., Barrio, J.R., In vivo brain imaging of tangle burden in humans. J. Mol. Neurosci. 19 (2002), 323–327.
193. Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Burggren, A.C., Cole, G.M., Vinters, H.V., Thompson, P.M., Huang, S.C., Satyamurthy, N., Phelps, M.E., Barrio, J.R., PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355 (2006), 2652–2663.
194. Small, G.W., Kepe, V., Siddarth, P., Ercoli, L.M., Merrill, D.A., Donoghue, N., Bookheimer, S.Y., Martinez, J., Omalu, B., Bailes, J., Barrio, J.R., PET Scanning of Brain Tau in Retired National Football League Players: Preliminary Findings. Am. J. Geriatr. Psychiatry 21 (2013), 138–144.
195. Small, G.W., Neuroimaging as a diagnostic tool in dementia with Lewy bodies. Demen. Geriatr. Cogn. Disord. 17:Suppl. 1 (2004), 25–31.
196. Smid, L.M., Kepe, V., Vinters, H.V., Bresjanac, M., Toyokuni, T., Satyamurthy, N., Wong, K.P., Huang, S.C., Silverman, D.H., Miller, K., Small, G.W., Barrio, J.R., Postmortem 3-D brain hemisphere cortical tau and amyloid-beta pathology mapping and quantification as a validation method of neuropathology imaging. J. Alzheimers Dis. 36 (2013), 261–274.
197. Sojkova, J., Resnick, S.M., In vivo human amyloid imaging. Curr. Alzheimer Res. 8 (2011), 366–372.
198. Sojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.E., Kraut, M.A., Ferrucci, L., Pletnikova, O., Mathis, C.A., Klunk, W.E., O'Brien, R.J., Wong, D.F., Troncoso, J.C., Resnick, S.M., In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch. Neurol. 68 (2011), 232–240.
199. Sperling, R.A., Laviolette, P.S., O'Keefe, K., O'Brien, J., Rentz, D.M., Pihlajamaki, M., Marshall, G., Hyman, B.T., Selkoe, D.J., Hedden, T., Buckner, R.L., Becker, J.A., Johnson, K.A., Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63 (2009), 178–188.
200. Sperling, R.A., Jack, C.R. Jr., Aisen, P.S., Testing the right target and right drug at the right stage. Sci. Transl. Med., 3, 2011, 111cm133.
201. Sperling, R.A., Johnson, K.A., Doraiswamy, P.M., Reiman, E.M., Fleisher, A.S., Sabbagh, M.N., Sadowsky, C.H., Carpenter, A., Davis, M.D., Lu, M., Flitter, M., Joshi, A.D., Clark, C.M., Grundman, M., Mintun, M.A., Skovronsky, D.M., Pontecorvo, M.J., Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol. Aging 34 (2013), 822–831.
202. Sperling, R.A., Rentz, D.M., Johnson, K.A., Karlawish, J., Donohue, M., Salmon, D.P., Aisen, P., The A4 study: stopping AD before symptoms begin?. Sci. Transl. Med., 6, 2014 228fs213.
203. Storandt, M., Head, D., Fagan, A.M., Holtzman, D.M., Morris, J.C., Toward a multifactorial model of Alzheimer disease. Neurobiol. Aging, 2012.
204. Sundgren-Andersson, A.K., Svensson, S.P.S., Swahn, B.M., Juréus, A., Sandell, J., Johnson, A.E., Jeppsson, F., Neelissen, J.A.M., Halldin, C., Johnström, P., Schou, M., Cselényi, Z., Farde, L., AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of beta-amyloid deposits. Alzheimers Demen. 5 (2009), P267–P268 [abstract].
205. Tenovuo, O., Kemppainen, N., Aalto, S., Nagren, K., Rinne, J.O., Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J. Alzheimers Dis. 15 (2008), 351–355.
206. Thal, D.R., Del Tredici, K., Braak, H., Neurodegeneration in normal brain aging and disease. Sc.i Aging Knowledge Environ., 2004, 2004, pe26.
207. Thal, L.J., Kantarci, K., Reiman, E.M., Klunk, W.E., Weiner, M.W., Zetterberg, H., Galasko, D., Pratico, D., Griffin, S., Schenk, D., Siemers, E., The Role of Biomarkers in Clinical Trials for Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 20 (2006), 6–15.
208. Thompson, P.W., Ye, L., Morgenstern, J.L., Sue, L., Beach, T.G., Judd, D.J., Shipley, N.J., Libri, V., Lockhart, A., Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J. Neurochem. 109 (2009), 623–630.
209. Thurfjell, L., Lotjonen, J., Lundqvist, R., Koikkalainen, J., Soininen, H., Waldemar, G., Brooks, D.J., Vandenberghe, R., Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener. Dis. 10:1–4 (2012), 246–249.
210. Tolboom, N., Yaqub, M., van der Flier, W.M., Boellaard, R., Luurtsema, G., Windhorst, A.D., Barkhof, F., Scheltens, P., Lammertsma, A.A., van Berckel, B.N., Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J. Nucl. Med. 50 (2009), 191–197.
211. Van Heertum, R.L., Tikofsky, R.S., Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin. Nucl. Med. 33 (2003), 77–85.
212. Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G., Buckley, C., Owenius, R., Thurfjell, L., Farrar, G., Brooks, D.J., 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 68 (2010), 319–329.
213. Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., Van der Linden, A., Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 53 (2005), 607–613.
214. Verhoeff, N.P., Wilson, A.A., Takeshita, S., Trop, L., Hussey, D., Singh, K., Kung, H.F., Kung, M.P., Houle, S., In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12 (2004), 584–595.
215. Versijpt, J., Van Laere, K.J., Dumont, F., Decoo, D., Vandecapelle, M., Santens, P., Goethals, I., Audenaert, K., Slegers, G., Dierckx, R.A., Korf, J., Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiol. Aging 24 (2003), 553–561.
216. Villemagne, V.L., Rowe, C.C., Amyloid ligands for dementia. PET Clin. 5 (2010), 33–53.
217. Villemagne, V.L., Musachio, J.L., Scheffel, U., Arneric, S.P., Brioni, J.D., (eds.) Nicotine and Related Compounds as PET and SPECT Ligands. In Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities, 1998, John Wiley & Sons, New York, 235–250.
218. Villemagne, V.L., Rowe, C.C., Macfarlane, S., Novakovic, K., Masters, C.L., Imaginem Oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. J. Clin. Neurosci. 12 (2005), 221–230.
219. Villemagne, V.L., Pike, K.E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T.F., Currie, J., Chan, S.G., Jones, G., Tochon-Danguy, H., O'Keefe, G., Masters, C.L., Rowe, C.C., Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46 (2008), 1688–1697.
220. Villemagne, V.L., Ataka, S., Mizuno, T., Brooks, W.S., Wada, Y., Kondo, M., Jones, G., Watanabe, Y., Mulligan, R., Nakagawa, M., Miki, T., Shimada, H., O'Keefe, G.J., Masters, C.L., Mori, H., Rowe, C.C., High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 66 (2009), 1537–1544.
221. Villemagne, V.L., McLean, C.A., Reardon, K., Boyd, A., Lewis, V., Klug, G., Jones, G., Baxendale, D., Masters, C.L., Rowe, C.C., Collins, S.J., 11C-PiB PET studies in typical sporadic Creutzfeldt–Jakob disease. J. Neurol. Neurosurg. Psychiatry 80 (2009), 998–1001.
222. Villemagne, V.L., Ong, K., Mulligan, R.S., Holl, G., Pejoska, S., Jones, G., O'Keefe, G., Ackerman, U., Tochon-Danguy, H., Chan, J.G., Reininger, C.B., Fels, L., Putz, B., Rohde, B., Masters, C.L., Rowe, C.C., Amyloid imaging with 18F-florbetaben in alzheimer disease and other dementias. J. Nucl. Med. 52 (2011), 1210–1217.
223. Villemagne, V.L., Pike, K.E., Chetelat, G., Ellis, K.A., Mulligan, R.S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C.A., Klunk, W.E., Ames, D., Masters, C.L., Rowe, C.C., Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann. Neurol. 69 (2011), 181–192.
224. Villemagne, V.L., Mulligan, R.S., Pejoska, S., Ong, K., Jones, G., O'Keefe, G., Chan, J.G., Young, K., Tochon-Danguy, H., Masters, C.L., Rowe, C.C., Comparison of (11)C-PiB and (18)F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 39 (2012), 983–989.
225. Villemagne, V.L., Okamura, N., Pejoska, S., Drago, J., Mulligan, R.S., Chetelat, G., O'Keefe, G., Jones, G., Kung, H.F., Pontecorvo, M., Masters, C.L., Skovronsky, D.M., Rowe, C.C., Differential diagnosis in Alzheimer's disease and dementia with lewy bodies via VMAT2 and amyloid imaging. Neurodegener. Dis. 10 (2012), 161–165.
226. Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K.A., Salvado, O., Szoeke, C., Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, C.C., Masters, C.L., Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12 (2013), 357–367.
227. Wadghiri, Y.Z., Sigurdsson, E.M., Sadowski, M., Elliott, J.I., Li, Y., Scholtzova, H., Tang, C.Y., Aguinaldo, G., Pappolla, M., Duff, K., Wisniewski, T., Turnbull, D.H., Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 50 (2003), 293–302.
228. Wadghiri, Y.Z., Sigurdsson, E.M., Wisniewski, T., Turnbull, D.H., Magnetic resonance imaging of amyloid plaques in transgenic mice. Methods Mol. Biol. 299 (2005), 365–379.
229. Walker, L.C., Price, D.L., Voytko, M.L., Schenk, D.B., Labelling of cerebral amyloid in vivo with a monoclonal antibody. J. Neuropathol. Exp. Neurol. 53 (1994), 377–383.
230. Walker, Z., Costa, D.C., Walker, R.W., Shaw, K., Gacinovic, S., Stevens, T., Livingston, G., Ince, P., McKeith, I.G., Katona, C.L., Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J. Neurol. Neurosurg. Psychiatry 73 (2002), 134–140.
231. Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., Nordberg, A., Backman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, K., de Leon, M., DeCarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J., Jack, C., Jorm, A., Ritchie, K., van Duijn, C., Visser, P., Petersen, R.C., Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 256 (2004), 240–246.
232. Wolk, D.A., Grachev, I.D., Buckley, C., Kazi, H., Grady, M.S., Trojanowski, J.Q., Hamilton, R.H., Sherwin, P., McLain, R., Arnold, S.E., Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch. Neurol. 68 (2011), 1398–1403.
233. Wolk, D.A., Price, J.C., Madeira, C., Saxton, J.A., Snitz, B.E., Lopez, O.L., Mathis, C.A., Klunk, W.E., Dekosky, S.T., Amyloid imaging in dementias with atypical presentation. Alzheimers Demen., 2012.
234. Wolk, D.A., Zhang, Z., Boudhar, S., Clark, C.M., Pontecorvo, M.J., Arnold, S.E., Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J. Neurol. Neurosurg. Psychiatry 83 (2012), 923–926.
235. Wong, D.F., Rosenberg, P.B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H.T., Dannals, R.F., Nandi, A., Brasic, J.R., Ye, W., Hilton, J., Lyketsos, C., Kung, H.F., Joshi, A.D., Skovronsky, D.M., Pontecorvo, M.J., In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51 (2010), 913–920.
236. Wong, D.F., Moghekar, A.R., Rigamonti, D., Brasic, J.R., Rousset, O., Willis, W., Buckley, C., Smith, A., Gok, B., Sherwin, P., Grachev, I.D., An in vivo evaluation of cerebral cortical amyloid with [(18)F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. Mol. Imaging Biol., 2012.
237. Xu, Y., Jack, C.R.J., O'Brien, P.C., Kokmen, E., Smith, G.E., Ivnik, R.J., Boeve, B.F., Tangalos, R.G., Petersen, R.C., Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54 (2000), 1760–1767.
238. Ye, L., Morgenstern, J.L., Gee, A.D., Hong, G., Brown, J., Lockhart, A., Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J. Biol. Chem. 280 (2005), 23599–23604.
239. Ye, L., Velasco, A., Fraser, G., Beach, T.G., Sue, L., Osredkar, T., Libri, V., Spillantini, M.G., Goedert, M., Lockhart, A., In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J. Neurochem. 105 (2008), 1428–1437.
240. Zhang, W., Oya, S., Kung, M.P., Hou, C., Maier, D.L., Kung, H.F., F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl. Med. Biol. 32 (2005), 799–809.
241. Zhang, W., Oya, S., Kung, M.P., Hou, C., Maier, D.L., Kung, H.F., F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J. Med. Chem. 48 (2005), 5980–5988.
242. Zhuang, Z.P., Kung, M.P., Hou, C., Plossl, K., Skovronsky, D., Gur, T.L., Trojanowski, J.Q., Lee, V.M., Kung, H.F., IBOX(2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl. Med. Biol. 28 (2001), 887–894.
243. Zwan, M., van Harten, A., Ossenkoppele, R., Bouwman, F., Teunissen, C., Adriaanse, S., Lammertsma, A., Scheltens, P., van Berckel, B., van der Flier, W., Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J. Alzheimers Dis. 41 (2014), 801–807.